Perspective for prophylaxis and treatment of cervical cancer: An immunological approach

Marjorie Jenkins, Maurizio Chiriva-Internati, Leonardo Mirandola, Catherine Tonroy, Sean S. Tedjarati, Nicole Davis, Nicholas D'Cunha, Lukman Tijani, Fred Hardwick, Diane Nguyen, W. Martin Kast, Everardo Cobos

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.

Original languageEnglish (US)
Pages (from-to)3-21
Number of pages19
JournalInternational Reviews of Immunology
Issue number1
StatePublished - Feb 2012
Externally publishedYes


  • Cancer vaccines
  • Gynecologic oncology
  • HPV
  • Immunotherapy
  • Tumor prevention

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Perspective for prophylaxis and treatment of cervical cancer: An immunological approach'. Together they form a unique fingerprint.

Cite this